AC
Calmy, Alexandra
| Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
|---|---|---|---|---|---|---|---|
| Mycoplasma genitalium infection in Eswatini amid syndromic case management : prevalence, coinfections, diagnostic challenges and treatment gaps | BMC infectious diseases | 2025 | 9 | 56 | |||
| HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study | Clinical infectious diseases | 2025 | 11 | 64 | |||
| Low Trauma Fractures in People with HIV : Longitudinal Time Trends in the Swiss HIV Cohort Study 2009-2022 | Clinical infectious diseases | 2025 | 14 | 34 | |||
| Ciprofloxacin versus Aminoglycoside-Ciprofloxacin for Bubonic Plague | The New England journal of medicine | 2025 | 8 | 305 | |||
| Polygenic Risk Scores for Type 2 Diabetes in the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | 2025 | 20 | 0 | |||
| Machine Learning-based Prediction of Active Tuberculosis in People With HIV Using Clinical Data | Clinical infectious diseases | 2025 | 13 | 34 | |||
| Patient Experiences With Nirmatrelvir/Ritonavir for COVID-19 in a Collaborative Care Model : A Cross-Sectional Study on Self-Management, Information, and Medication Impact | Journal of patient experience | 2025 | 13 | 47 | |||
| Targeted approaches for acute HIV infection diagnosis in rural Eswatini | International journal of STD & AIDS | 2025 | 8 | 40 | |||
| Enjeux pharmaceutiques autour de la pénicilline G : exemple de la syphilis | Revue médicale suisse | 2025 | 11 | 0 | |||
| Tecovirimat at a crossroads : What the PALM007 trial tells us | Med | 2025 | 9 | 1 | |||
| Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study) : an international survey and Delphi process | The lancet. HIV | 2025 | 7 | 51 | |||
| Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa : a modelling study | The lancet. HIV | 2025 | 6 | 42 | |||
| Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV : the Swiss HIV Cohort Study | The Journal of infectious diseases | 2025 | 10 | 35 | |||
| Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025 | HIV medicine | 2025 | 17 | 51 | |||
| Infection with Mycobacterium tuberculosis alters the antibody response to HIV-1 | PLOS pathogens | 2025 | 9 | 72 | |||
| Late Re-Engagement Into HIV Care Among Adults in the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | 2025 | 15 | 0 | |||
| Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program : A Data Linkage Study of Claims and Swiss HIV Cohort Study Data | Open forum infectious diseases | 2025 | 10 | 10 | |||
| Vaccination contre les infections à papillomavirus humains. Indications, couverture et perspectives | Revue médicale suisse | 2025 | 6 | 0 | |||
| Frequent hepatitis B surface antigen (HBsAg) clearance during tenofovir therapy in persons with HIV/hepatitis B virus coinfection | HIV medicine | 2025 | 14 | 0 | |||
| VIH : ce qui a changé en 2024 | Revue médicale suisse | 2025 | 12 | 1 | |||
| Leukocyte count and new-onset diabetes mellitus in people with HIV : A longitudinal study | HIV medicine | 2025 | 14 | 14 | |||
| Willingness to participate in clinical trials and expectations towards antiretroviral therapy among heavily treatment-experienced people living with HIV : A feasibility survey | HIV medicine | 2025 | 13 | 36 | |||
| High Burden of Symptomatic and Asymptomatic Sexually Transmitted Infections in a Routine Decentralised HIV Care Setting in Eswatini : A Cross‐Sectional Study | TM & IH. Tropical medicine and international health | 2025 | 13 | 112 | |||
| Retiring the language of first-line and second-line ART | The lancet. HIV | 2025 | 14 | 13 | |||
| Implementing a randomization consent to enable Trials within Cohorts in the Swiss HIV Cohort Study - A mixed-methods study | Journal of clinical epidemiology | 2025 | 10 | 51 | |||
| International healthcare workers' experiences and perceptions of the 2022 multi-country mpox outbreak | PLOS global public health | 2025 | 5 | 7 | |||
| SARS-CoV-2 cross-sectional serosurvey across three HIV-1 therapeutic clinical trials in Africa | AIDS | 2025 | 9 | 23 | |||
| Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease : A European Multicenter Mpox Observational Cohort Study (MOSAIC) | Clinical infectious diseases | 2025 | 9 | 22 | |||
| Type I interferon autoantibody footprints reveal neutralizing mechanisms and allow inhibitory decoy design | The Journal of experimental medicine | 2025 | 8 | 66 | |||
| Predictive risk assessment and targeted testing could enhance STI diagnosis in a high HIV prevalence setting in Eswatini | Scientific reports | 2025 | 8 | 22 | |||
| Low sensitivity of the fourth-generation antigen/antibody HIV rapid diagnostic test Determine™ HIV Early Detect for detection of acute HIV infection at the point of care in rural Eswatini : a diagnostic accuracy study | Journal of the International AIDS Society | 2025 | 15 | 244 | |||
| Gender and geographical bias in the editorial decision-making process of biomedical journals : a case-control study | BMJ evidence-based medicine | 2024 | 36 | 86 | |||
| External Validation of Serologic Scores for the Detection of Liver Steatosis Among People With HIV | Open forum infectious diseases | 2024 | 8 | 44 | |||
| Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort : a prospective observational cohort study | The lancet. HIV | 2024 | 89 | 0 | |||
| Time Trends in Causes of Death in People With HIV : Insights From the Swiss HIV Cohort Study | Clinical infectious diseases | 2024 | 9 | 67 | |||
| Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine : a multicenter prospective observational study in Switzerland | The Lancet regional health. Europe | 2024 | 6 | 51 | |||
| Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells | Nature medicine | 2024 | 9 | 13 | |||
| Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression : Results Through Week 144 of the SIMPL'HIV Trial | Open forum infectious diseases | 2024 | 6 | 54 | |||
| Safety and efficacy of doravirine as first-line therapy in adults with HIV-1 : week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials | The lancet. HIV | 2024 | 7 | 0 | |||
| Characterization and Determinants of Long-Term Immune Recovery Under Suppressive Antiretroviral Therapy | Journal of acquired immune deficiency syndromes | 2024 | 9 | 24 | |||
| Rendre la recherche clinique plus attractive | Revue médicale suisse | 2024 | 9 | 0 | |||
| Gender Disparities in Statin Prescriptions in People With HIV With Low/Moderate to High Cardiovascular Risk | Open forum infectious diseases | 2024 | 4 | 22 | |||
| Singularités du Covid-19 chez les personnes immunosupprimées | Revue médicale suisse | 2024 | 12 | 13 | |||
| Infectious disease events in people with HIV receiving kidney transplantation : Analysis of the Swiss HIV Cohort Study and the Swiss Transplant Cohort Study | BMC infectious diseases | 2024 | 64 | 110 | |||
| Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV | Frontiers in pharmacology | 2024 | 6 | 25 | |||
| Novel anti-obesity drugs for people with HIV | The lancet. HIV | 2024 | 11 | 0 | |||
| Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV | Clinical infectious diseases | 2024 | 5 | 29 | |||
| Cohort profile : the Swiss Mother and Child HIV Cohort Study (MoCHiV) | BMJ open | 2024 | 5 | 10 | |||
| Patient and public involvement in HIV research : a mapping review and development of an online evidence map | Journal of the International AIDS Society | 2024 | 3 | 36 | |||
| Effectively protecting health care workers as clade 1 mpox epidemic complexifies : a call for vaccine and antivirals deployment | Journal of travel medicine | 2024 | 13 | 17 | |||
| Self-reported neurocognitive complaints in the Swiss HIV Cohort Study : a viral genome-wide association study | Brain communications | 2024 | 11 | 26 | |||
| Impact of hormonal therapy on HIV-1 immune markers in cis women and gender minorities | HIV medicine | 2024 | 6 | 26 | |||
| Transcriptional profile of Mycobacterium tuberculosis infection in people living with HIV | iScience | 2024 | 8 | 14 | |||
| Costs and acceptability of simplified monitoring in HIV-suppressed patients switching to dual therapy : the SIMPL'HIV open-label, factorial randomised controlled trial | Swiss medical weekly | 2024 | 12 | 47 | |||
| Immune response to the recombinant herpes zoster vaccine in people living with HIV over 50 years of age compared to non-HIV age-/gender-matched controls (SHINGR’HIV) : a multicenter, international, non-randomized clinical trial study protocol | BMC infectious diseases | 2024 | 124 | 190 | |||
| Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort Study | The Journal of infectious diseases | 2024 | 9 | 26 | |||
| Similar Viral and Immune Characteristics of Kaposi Sarcoma in ART-treated People Living With HIV and Older Patients With Classic Kaposi Sarcoma | Open forum infectious diseases | 2024 | 6 | 30 | |||
| Circulating HBV RNA and Hepatitis B Core-Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy | The Journal of infectious diseases | 2024 | 5 | 22 | |||
| Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy : 48-week results of a phase 3, randomised, open-label, non-inferiority trial | The lancet. HIV | 2024 | 15 | 0 | |||
| Population Pharmacokinetics of Cabotegravir Following Oral Administration and Long‐Acting Intramuscular Injection in Real‐World People with HIV | Clinical pharmacology and therapeutics | 2024 | 92 | 204 | |||
| Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3) | The Journal of infectious diseases | 2024 | 520 | 516 | |||
| Long-term trends in hepatitis C prevalence, treatment uptake and liver-related events in the Swiss HIV Cohort Study | Liver international | 2024 | 6 | 42 | |||
| Loss of tolerance precedes triggering and lifelong persistence of pathogenic type I interferon autoantibodies | The Journal of experimental medicine | 2024 | 8 | 51 | |||
| Booster-free anti-retroviral therapy for persons living with HIV and multidrug resistance (B-Free) : protocol for a multicentre, multistage, randomised, controlled, non-inferiority trial | BMJ open | 2024 | 3 | 20 | |||
| Trends in Mortality in People With HIV From 1999 through 2020 : A Multicohort Collaboration | Clinical infectious diseases | 2024 | 7 | 10 | |||
| Study protocol for assessment of the efficacy of calcium dobesilate versus placebo on SARS-CoV-2 viral load in outpatients with COVID-19 (CADOVID study): a randomised, placebo-controlled, double-blind, monocentric phase II trial | BMJ open | 2024 | 29 | 93 | |||
| Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy | HIV medicine | 2024 | 15 | 40 | |||
| Mpox : The alarm went off. Have we gone back to sleep ? | PLoS neglected tropical diseases | 2024 | 9 | 23 | |||
| Frequency matters: comparison of drug resistance mutation detection by Sanger and next-generation sequencing in HIV-1 | The journal of antimicrobial chemotherapy | 2023 | 100 | 0 | |||
| Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy | Clinical infectious diseases | 2023 | 105 | 137 | |||
| Antiretroviral Drug Exposure and Response in Obese and Morbidly Obese People With Human Immunodeficiency Virus (HIV) : A Study Combining Modelling and Swiss HIV Cohort Data | Clinical infectious diseases | 2023 | 116 | 94 | |||
| Viral suppression and retention in HIV care during the postpartum period among women living with HIV : a longitudinal multicenter cohort study | The Lancet regional health. Europe | 2023 | 65 | 19 | |||
| VIH : zoom sur les traitements injectables à longue durée d’action | Revue médicale suisse | 2023 | 124 | 199 | |||
| Effect of SLCO1B1 c.521T>C polymorphism on the lipid response to statins in people living with HIV on a boosted protease inhibitor‐containing regimen | British journal of clinical pharmacology | 2023 | 106 | 96 | |||
| Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon : Week 192 Data of the NAMSAL-ANRS-12313 Study | Open forum infectious diseases | 2023 | 8 | 39 | |||
| Mpox in people with advanced HIV infection: a global case series | Lancet | 2023 | 142 | 462 | |||
| External validation of the Dat'AIDS score : A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older | HIV medicine | 2023 | 95 | 75 | |||
| Low prevalence of asymptomatic mpox in populations at high risk | The Lancet microbe | 2023 | 127 | 51 | |||
| An Automated Literature Review Tool (LiteRev) for Streamlining and Accelerating Research Using Natural Language Processing and Machine Learning: Descriptive Performance Evaluation Study | JMIR. Journal of medical internet research | 2023 | 173 | 254 | |||
| Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study | BMC pharmacology & toxicology | 2023 | 62 | 145 | |||
| Hepatitis B Virus (HBV) Replication During Tenofovir Therapy Is Frequent in Human Immunodeficiency Virus/HBV Coinfection | Clinical infectious diseases | 2023 | 112 | 0 | |||
| Remise des autotests VIH en pharmacie d’officine. État des lieux et recommandations de pratique pour une collaboration interprofessionnelle | Revue médicale suisse | 2023 | 5 | 12 | |||
| Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial | Critical care | 2023 | 89 | 71 | |||
| Incidence of sexually transmitted infections and association with behavioural factors: Time-to-event analysis of a large pre-exposure prophylaxis (PrEP) cohort | HIV medicine | 2023 | 91 | 296 | |||
| Comparison of five different risk scores to predict incident type 2 diabetes in the Swiss HIV cohort study | AIDS | 2023 | 117 | 54 | |||
| Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV : The Swiss HIV Cohort Study | The Journal of infectious diseases | 2023 | 97 | 56 | |||
| Antibody Response After the Third SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients and People Living With HIV (COVERALL-2) | Open forum infectious diseases | 2023 | 92 | 79 | |||
| Understanding the Decline of Incident, Active Tuberculosis in People With Human Immunodeficiency Virus (HIV) in Switzerland | Clinical infectious diseases | 2023 | 106 | 53 | |||
| A Case of Mpox Reinfection | Clinical infectious diseases | 2023 | 76 | 101 | |||
| No time for complacency on COVID-19 in Europe | Lancet | 2023 | 147 | 52 | |||
| The international Unity study for antivirals against mpox is a blueprint for future epidemics | Nature medicine | 2023 | 141 | 0 | |||
| Triggers of change in sexual behavior among people with HIV: The Swiss U = U statement and Covid-19 compared | The Journal of infectious diseases | 2023 | 118 | 85 | |||
| Does menopause transition influence viral suppression and adherence in women living with HIV? | Journal of acquired immune deficiency syndromes | 2023 | 85 | 46 | |||
| Multicentric evaluation of a specific intrathecal anti-Treponema pallidum IgG index as a diagnostic biomarker of neurosyphilis: results from a retro-prospective case–control study | Sexually transmitted infections | 2023 | 172 | 0 | |||
| Polygenic Risk Scores for Prediction of Subclinical Coronary Artery Disease in Persons With Human Immunodeficiency Virus (HIV): The Swiss HIV Cohort Study | Clinical infectious diseases | 2023 | 103 | 45 | |||
| Antibody Response After Third Vaccination With mRNA-1273 or BNT162b2 : Extension of a Randomized Controlled SARS-CoV-2 Noninferiority Vaccine Trial in Patients With Different Levels of Immunosuppression (COVERALL-2) | Open forum infectious diseases | 2023 | 140 | 93 | |||
| Sexual Behaviour and STI Incidence in Sexually Active MSM Living With HIV in Times of COVID-19 | Open forum infectious diseases | 2023 | 128 | 156 | |||
| Prevalence of HIV-1 drug resistance mutations in proviral DNA in the Swiss HIV Cohort Study, a retrospective study from 1995 to 2018 | The journal of antimicrobial chemotherapy | 2023 | 146 | 232 | |||
| Effect of therapeutic anticoagulation on gas exchange in mechanically ventilated COVID-19 patients: A secondary analysis of the COVID-HEP trial | Thrombosis research | 2023 | 318 | 77 | |||
| SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients | Vaccines | 2023 | 92 | 115 | |||
| Women with HIV transitioning through menopause: Insights from the Swiss HIV Cohort Study (SHCS) | HIV medicine | 2022 | 149 | 145 | |||
| Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial | Trials | 2022 | 135 | 181 | |||
| Rethinking treatment paradigms for the deployment of SARS-CoV-2 antiviral drugs on the shifting landscape of new variants | Frontiers in microbiology | 2022 | 259 | 71 | |||
| Cardiovascular risk assessment in people living with HIV compared to the general population | European journal of preventive cardiology | 2022 | 224 | 163 | |||
| Impact on HIV-1 RNA Levels and Antibody Responses Following SARS-CoV-2 Vaccination in HIV-Infected Individuals | Frontiers in immunology | 2022 | 256 | 103 | |||
| Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics | Journal of acquired immune deficiency syndromes | 2022 | 188 | 74 | |||
| An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters | Viruses | 2022 | 98 | 25 | |||
| CD4:CD8 Ratio and CD8 Cell Count and Their Prognostic Relevance for Coronary Heart Disease Events and Stroke in Antiretroviral Treated Individuals: The Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | 2022 | 101 | 96 | |||
| Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland | Pharmaceutics | 2022 | 71 | 136 | |||
| Immunocompromised patients have been neglected in COVID-19 trials: a call for action | Clinical microbiology and infection | 2022 | 74 | 88 | |||
| Female Genital Mutilation/Cutting in the Swiss HIV Cohort Study: A Cross-Sectional Study | Journal of immigrant and minority health | 2022 | 91 | 105 | |||
| La variole du singe: Une nouvelle épidémie – réponses aux questions fréquentes dans la pratique | Primary and hospital care | 2022 | 212 | 91 | |||
| A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab | Lancet. Infectious diseases | 2022 | 118 | 210 | |||
| Impact of Latent Tuberculosis on Diabetes | The Journal of infectious diseases | 2022 | 221 | 0 | |||
| Accelerating investigation of new HIV drugs in pregnancy : advancing the research agenda from theory to action | Journal of the International AIDS Society | 2022 | 79 | 51 | |||
| Use of Ritonavir-Boosted Nirmatrelvir in Pregnancy | Clinical infectious diseases | 2022 | 116 | 28 | |||
| Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period | AIDS | 2022 | 768 | 233 | |||
| Dexamethasone and Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia | JAMA | 2022 | 171 | 0 | |||
| How mHealth Can Contribute to Improving the Continuum of Care: A Scoping Review Approach to the Case of Human Immunodeficiency Virus in Sub-Saharan Africa | Public health reviews | 2022 | 102 | 43 | |||
| Transfer of antiretroviral drugs into breastmilk : a prospective study from the Swiss Mother and Child HIV Cohort Study | The journal of antimicrobial chemotherapy | 2022 | 96 | 63 | |||
| A Systematic Molecular Epidemiology Screen Reveals Numerous Human Immunodeficiency Virus (HIV) Type 1 Superinfections in the Swiss HIV Cohort Study | The Journal of infectious diseases | 2022 | 126 | 0 | |||
| Response to comments by Taramasso and colleagues on weight gain stopping/switch rules for antiretroviral clinical trials | AIDS | 2022 | 59 | 0 | |||
| How the COVID-19 Pandemic Alters the Landscapes of the HIV and Tuberculosis Epidemics in South Africa: A Case Study and Future Directions | Epidemiologia | 2022 | 85 | 176 | |||
| VIH et Covid-19 : deux pandémies virales en interaction | Revue médicale suisse | 2022 | 78 | 96 | |||
| Dexamethasone exposure in normal-weight and obese hospitalized COVID-19 patients: An observational exploratory trial | Clinical and translational science | 2022 | 153 | 133 | |||
| Anticholinergic medication use in elderly people living with HIV and self-reported neurocognitive impairment: a prospective cohort study | The journal of antimicrobial chemotherapy | 2022 | 103 | 0 | |||
| Therapeutic anticoagulation to prevent thrombosis, coagulopathy, and mortality in severe COVID-19: The Swiss COVID-HEP randomized clinical trial | Research and practice in thrombosis and haemostasis | 2022 | 249 | 275 | |||
| Anticholinergic and sedative medications are associated with neurocognitive performance of well treated people with human immunodeficiency virus | Open forum infectious diseases | 2022 | 93 | 139 | |||
| Facilitators and barriers of women's participation in HIV clinical research in Switzerland: A qualitative study | HIV medicine | 2022 | 365 | 179 | |||
| Quantifying and predicting ongoing Human Immunodeficiency Virus Type 1 (HIV-1) transmission dynamics in Switzerland using a distance-based clustering approach | The Journal of infectious diseases | 2022 | 143 | 2 | |||
| A highly virulent variant of HIV-1 circulating in the Netherlands | Science | 2022 | 197 | 90 | |||
| Bas les masques, et après ? | Revue médicale suisse | 2022 | 66 | 70 | |||
| Risk Factors and Incidence of Sexually Transmitted Infections in the Swiss HIV Cohort Study | Open forum infectious diseases | 2022 | 214 | 601 | |||
| Decreasing incidence and determinants of Bacterial Pneumonia in people with HIV: The Swiss HIV Cohort Study | The Journal of infectious diseases | 2022 | 140 | 214 | |||
| Developing and testing a Corona VaccinE tRiAL pLatform (COVERALL) to study Covid-19 vaccine response in immunocompromised patients | BMC infectious diseases | 2022 | 143 | 81 | |||
| Decrease of condom use in heterosexual couples and its impact on pregnancy rates: the Swiss HIV Cohort Study (SHCS) | HIV medicine | 2022 | 117 | 110 | |||
| Cohort Profile Update: The Swiss HIV Cohort Study (SHCS) | International journal of epidemiology | 2022 | 262 | 0 | |||
| Approaches to accelerating the study of new antiretrovirals in pregnancy | Journal of the International AIDS Society | 2022 | 76 | 165 | |||
| Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial | British journal of clinical pharmacology | 2021 | 222 | 0 | |||
| Cyber harassment of female scientists will not be the new norm | The Lancet Infectious Diseases | 2021 | 256 | 208 | |||
| Network Analysis of Outpatients to Identify Predictive Symptoms and Combinations of Symptoms Associated With Positive/Negative SARS-CoV-2 Nasopharyngeal Swabs | Frontiers in Medicine | 2021 | 219 | 151 | |||
| Predicting, Diagnosing, and Treating Acute and Early HIV Infection in a Public Sector Facility in Eswatini | Journal of acquired immune deficiency syndromes | 2021 | 181 | 191 | |||
| Telomere Length, Traditional Risk Factors, Factors Related to Human Immunodeficiency Virus (HIV) and Coronary Artery Disease Events in Swiss Persons Living With HIV | Clinical infectious diseases | 2021 | 197 | 0 | |||
| Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study | Open Forum Infectious Diseases | 2021 | 320 | 185 | |||
| Effect of Rosuvastatin Therapy on Biomarkers of Inflammation and Immune Activation in People With Human Immunodeficiency Virus at Intermediate Cardiovascular Risk | The Journal of infectious diseases | 2021 | 252 | 9 | |||
| Kaposi sarcoma in antiretroviral therapy-treated people with HIV: a wake-up call for research on human herpesvirus-8 | AIDS | 2021 | 268 | 290 | |||
| Predictors of virological failure and time to viral suppression of first-line integrase inhibitor-based antiretroviral treatment | Clinical infectious diseases | 2021 | 204 | 138 | |||
| The role of Human Immunodeficiency Virus (HIV) asymptomatic status when starting antiretroviral therapy on adherence and treatment outcomes and implications for test and treat: the swiss HIV Cohort Study | Clinical Infectious Diseases | 2021 | 163 | 0 | |||
| VIH/sida - VIH au temps du Covid-19 : rencontre de deux pandémies | Revue médicale suisse | 2021 | 215 | 122 | |||
| Nouveautés dans le diagnostic du VIH | Forum médical suisse | 2021 | 270 | 379 | |||
| Caring for people living with HIV during the global coronavirus disease 2019 pandemic | AIDS | 2021 | 249 | 0 | |||
| Changes in alanine aminotransferase levels after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-positive people without viral hepatitis in the Swiss HIV Cohort Study | HIV medicine | 2021 | 326 | 0 | |||
| Alcohol consumption and neurocognitive deficits in people with well-treated HIV in Switzerland | PloS one | 2021 | 215 | 319 | |||
| Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV | AIDS | 2021 | 211 | 145 | |||
| Data linkage to evaluate the long-term risk of HIV infection in individuals seeking post-exposure prophylaxis | Nature communications | 2021 | 85 | 13 | |||
| Weight gain stopping/switch rules for antiretroviral clinical trials | AIDS | 2021 | 188 | 95 | |||
| Prophylaxis for COVID-19: a systematic review | Clinical microbiology and infection | 2021 | 91 | 116 | |||
| Analysis of inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study reveals gender inequity | The journal of antimicrobial chemotherapy | 2021 | 179 | 0 | |||
| Identifying and characterizing trans women in the swiss HIV Cohort Study as an epidemiologically distinct risk group | Clinical Infectious Diseases | 2021 | 200 | 0 | |||
| Post-exposure Lopinavir-Ritonavir Prophylaxis versus Surveillance for Individuals Exposed to SARS-CoV-2: The COPEP Pragmatic Open-Label, Cluster Randomized Trial | EClinicalMedicine | 2021 | 648 | 177 | |||
| Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study | Annals of internal medicine | 2021 | 213 | 0 | |||
| Prevalence of Potential Drug-Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors | Clinical infectious diseases | 2021 | 187 | 0 | |||
| Representations and Willingness of People Living With HIV in Switzerland to Participate in HIV Cure Trials: The Case of Gene-Modified Cell Therapies | Journal of acquired immune deficiency syndromes | 2021 | 177 | 0 | |||
| Cohort-Derived Machine Learning Models for Individual Prediction of Chronic Kidney Disease in People Living With Human Immunodeficiency Virus: A Prospective Multicenter Cohort Study | The Journal of infectious diseases | 2021 | 107 | 38 | |||
| Impact of rosuvastatin on atherosclerosis in people with hiv at moderate cardiovascular risk: a randomised, controlled trial | AIDS | 2021 | 675 | 281 | |||
| Clinical outcomes of 2-drug regimens vs 3-drug regimens in antiretroviral treatment-experienced people living with Human Immunodeficiency Virus | Clinical infectious diseases | 2021 | 171 | 161 | |||
| The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study | Journal of clinical medicine | 2021 | 84 | 94 | |||
| Possible link between anosmia and COVID-19: sniffing out the truth | European Archives of Oto-Rhino-Laryngology | 2020 | 196 | 181 | |||
| Differences in social and mental well-being of long-term survivors among people who inject drugs and other participants in the Swiss HIV Cohort Study : 1980-2018 | Antiviral therapy | 2020 | 73 | 0 | |||
| Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines | The Lancet HIV | 2020 | 227 | 118 | |||
| Evolocumab treatment in patients with HIV and hypercholesterolemia/mixed dyslipidemia: BEIJERINCK study design and baseline characteristics | American Heart Journal | 2020 | 256 | 120 | |||
| Antiretroviral Drugs Associated With Subclinical Coronary Artery Disease in the Swiss Human Immunodeficiency Virus Cohort Study | Clinical Infectious Diseases | 2020 | 233 | 0 | |||
| Clinicopathologic Aspects of a Papulovesicular Eruption in a Patient With COVID-19 | JAMA Dermatology | 2020 | 315 | 0 | |||
| Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study | Journal of the American College of Cardiology | 2020 | 412 | 199 | |||
| Buyers' club : une alternative pour l'accès au traitement ? | Revue médicale suisse | 2020 | 413 | 234 | |||
| Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study | The Journal of infectious diseases | 2020 | 212 | 220 | |||
| Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV | PLoS biology | 2020 | 100 | 31 | |||
| Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs | Swiss Medical Weekly | 2020 | 507 | 421 | |||
| Towards the real-time inclusion of sex- and age-disaggregated data in pandemic responses | BMJ global health | 2020 | 101 | 51 | |||
| Mycobaterium fortuitum disseminated infection in an immunocompetent patient without predisposing factors | BMJ case reports | 2020 | 183 | 0 | |||
| Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPL'HIV trial | PLoS medicine | 2020 | 228 | 223 | |||
| Macrophage activation syndrome as an unusual presentation of paucisymptomatic severe acute respiratory syndrome coronavirus 2 infection: A case report | Medicine (Baltimore) | 2020 | 390 | 128 | |||
| HIV and antiretroviral therapy-related fat alterations | Nature Reviews. Disease Primers | 2020 | 222 | 20 | |||
| The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile | HIV Medicine | 2020 | 411 | 205 | |||
| Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis | EClinicalMedicine | 2020 | 105 | 78 | |||
| First reported case of Rothia dentocariosa spondylodiscitis in an immunocompetent patient | IDCases | 2020 | 526 | 248 | |||
| How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population? | HIV medicine | 2020 | 118 | 53 | |||
| Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy | Open Forum Infectious Diseases | 2020 | 236 | 130 | |||
| Longitudinal Progression of Subclinical Coronary Atherosclerosis in Swiss HIV-Positive Compared With HIV-Negative Persons Undergoing Coronary Calcium Score Scan and CT Angiography | Open forum infectious diseases | 2020 | 139 | 103 | |||
| Heritability of the HIV-1 reservoir size and decay under long-term suppressive ART | Nature Communications | 2020 | 262 | 85 | |||
| Emergence of drug resistance in the Swiss HIV Cohort Study under potent antiretroviral therapy is observed in socially disadvantaged patients | Clinical Infectious Diseases | 2020 | 371 | 3 | |||
| C-terminus apoa-1 mimetic peptides to detect cognate auto-antibodies and reverse HIV-induced foam cell formation | Atherosclerosis | 2020 | 250 | 0 | |||
| Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19 : initial assessment | Journal of the International AIDS Society | 2020 | 72 | 26 | |||
| Dexamethasone and remdesivir: finding method in the COVID-19 madness | The Lancet microbe | 2020 | 251 | 45 | |||
| Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting | Journal of Acquired Immune Deficiency Syndromes | 2020 | 236 | 131 | |||
| Cobicistat : A case of mislabelled drug-drug interaction risk? | British journal of clinical pharmacology | 2020 | 72 | 20 | |||
| Efficacy of pragmatic same-day ring prophylaxis for adult individuals exposed to SARS-CoV-2 in Switzerland (COPEP): protocol of an open-label cluster randomised trial | BMJ Open | 2020 | 269 | 109 | |||
| VIH: prévention, traitement et perspectives | Revue médicale suisse | 2020 | 380 | 280 | |||
| Impact of the M184V/I Mutation on the efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV treatment-experienced patients | Open Forum Infectious Diseases | 2019 | 303 | 252 | |||
| Next-Generation Sequencing for the Diagnosis of Challenging Culture-Negative Endocarditis | Frontiers in Medicine | 2019 | 387 | 274 | |||
| Female Genital Schistosomiasis and HIV: Research Urgently Needed to Improve Understanding of the Health Impacts of This Important Coinfection | Journal of acquired immune deficiency syndromes | 2019 | 188 | 0 | |||
| Exploring the Patterns of Use and Acceptability of Mobile Phones Among People Living With HIV to Improve Care and Treatment: Cross-Sectional Study in Three Francophone West African Countries | JMIR mhealth and uhealth | 2019 | 203 | 92 | |||
| Clinical, behavioral and biomarker predictors of PCSK9 levels in HIV-infected patients naïve of statin therapy: A cross-sectional analysis from the Swiss HIV cohort | Atherosclerosis | 2019 | 435 | 1 | |||
| Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis | Osteoporosis International | 2019 | 359 | 1 | |||
| Nouveautés dans le dépistage, la prévention et la prise en charge du VIH en 2018 | Revue médicale suisse | 2019 | 72 | 39 | |||
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials | Lancet | 2019 | 96 | 0 | |||
| Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study | The lancet. HIV | 2019 | 87 | 73 | |||
| Reply to “Antiretroviral therapy options in people living with HIV at risk of or with osteoporosis. Comment on: Diagnosis, prevention, and treatment of bone fragility in people living with HIV: a position statement from the Swiss Association against Osteoporosis” by S. Noe, H. Jaeger, E. Wolf | Osteoporosis international | 2019 | 54 | 0 | |||
| Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence | The journal of antimicrobial chemotherapy | 2019 | 84 | 0 | |||
| Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1 | New England Journal of Medicine | 2019 | 295 | 174 | |||
| Mortality from suicide among people living with HIV and the general Swiss population: 1988-2017 | Journal of the International AIDS society | 2019 | 391 | 163 | |||
| A systematic phylogenetic approach to study the interaction of HIV-1 with coinfections, noncommunicable diseases, and opportunistic diseases | The Journal of Infectious Diseases | 2019 | 354 | 0 | |||
| Why do sub‐Saharan Africans present late for HIV care in Switzerland ? | HIV medicine | 2019 | 89 | 0 | |||
| Viral diversity based on next-generation sequencing of HIV-1 provides precise estimates of infection recency and time since infection | The Journal of Infectious Diseases | 2019 | 303 | 0 | |||
| Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort | BMC infectious diseases | 2019 | 227 | 94 | |||
| Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factors | F1000Research | 2019 | 259 | 115 | |||
| Impact of Boosted Antiretroviral Therapy on the Pharmacokinetics and Efficacy of Clopidogrel and Prasugrel Active Metabolites | Clinical Pharmacokinetics | 2018 | 737 | 843 | |||
| Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis | F1000Research | 2018 | 158 | 182 | |||
| Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort | AIDS | 2018 | 187 | 0 | |||
| Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study | Liver International | 2018 | 485 | 0 | |||
| Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients | Journal of Infection | 2018 | 580 | 1 | |||
| Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens | HIV Medicine | 2018 | 378 | 185 | |||
| Expert consensus statement on the science of HIV in the context of criminal law | Journal of the International AIDS Society | 2018 | 134 | 695 | |||
| Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study | Virus Evolution | 2018 | 388 | 110 | |||
| High Rates of Subsequent Asymptomatic Sexually Transmitted Infections and Risky Sexual Behavior in Patients Initially Presenting With Primary Human Immunodeficiency Virus-1 Infection | Clinical Infectious Diseases | 2018 | 405 | 0 | |||
| A buyers' club to improve access to hepatitis C treatment for vulnerable populations | Swiss Medical Weekly | 2018 | 1,236 | 483 | |||
| Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule | Clinical infectious diseases | 2018 | 90 | 0 | |||
| Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study | Kidney International Reports | 2018 | 495 | 162 | |||
| Traitements antirétroviraux : vers un allègement ? | Revue médicale suisse | 2018 | 71 | 90 | |||
| The cumulative impact of harm reduction on the swiss HIV epidemic: cohort study, mathematical model, and phylogenetic analysis | Open Forum Infectious Diseases | 2018 | 378 | 227 | |||
| Universal test and treat is not associated with sub‐optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial | Journal of the International AIDS Society | 2018 | 132 | 55 | |||
| Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity | Molecular Biology and Evolution | 2018 | 505 | 229 | |||
| Will NNRTIs be driving forward again ? | The lancet. HIV | 2018 | 57 | 0 | |||
| Extracavitary primary effusion lymphoma (PEL) presenting as bilateral adrenal gland involvement in an HIV-positive patient | Annals of Hematology | 2018 | 400 | 0 | |||
| Stable HIV-1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study | HIV Medicine | 2018 | 335 | 130 | |||
| Time to overcome pretreatment HIV drug resistance | The Lancet Infectious Diseases | 2018 | 396 | 228 | |||
| Managing Advanced HIV Disease in a Public Health Approach | Clinical infectious diseases | 2018 | 84 | 101 | |||
| Evaluation of the Xpert MTB/RIF assay for the diagnosis of smear-negative pulmonary and extrapulmonary tuberculosis in Madagascar | International journal of infectious diseases | 2018 | 211 | 136 | |||
| Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all? | HIV Medicine | 2018 | 371 | 0 | |||
| Quantifying the drivers of HIV transmission and prevention in men who have sex with men: a population model-based analysis in Switzerland | HIV Medicine | 2018 | 609 | 0 | |||
| Subclinical coronary artery disease in Swiss HIV-positive and HIV-negative persons | European heart journal | 2018 | 103 | 0 | |||
| The Persistent Challenge of Advanced HIV Disease and AIDS in the Era of Antiretroviral Therapy | Clinical infectious diseases | 2018 | 58 | 20 | |||
| Anti-inflammatory therapy in well controlled HIV infection | The Lancet HIV | 2018 | 437 | 0 | |||
| Benefits and risks of rapid initiation of antiretroviral therapy | AIDS | 2018 | 474 | 333 | |||
| Tracing HIV-1 strains that imprint broadly neutralizing antibody responses | Nature | 2018 | 183 | 0 | |||
| Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity | The Journal of experimental medicine | 2018 | 309 | 136 | |||
| Universal test and treat and the HIV epidemic in rural South Africa : a phase 4, open-label, community cluster randomised trial | The lancet. HIV | 2018 | 78 | 108 | |||
| Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals | Medicine (Philadelphia) | 2017 | 411 | 184 | |||
| Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population | AIDS | 2017 | 413 | 327 | |||
| Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis | eLife | 2017 | 501 | 191 | |||
| Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis | The Lancet HIV | 2017 | 444 | 0 | |||
| Bone health in HIV and hepatitis B or C infections | Therapeutic advances in musculoskeletal disease | 2017 | 546 | 323 | |||
| Hepatitis delta-associated mortality in HIV/HBV-coinfected patients | Journal of Hepatology | 2017 | 430 | 549 | |||
| CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study | Journal of Antimicrobial Chemotherapy | 2017 | 420 | 0 | |||
| Ethnicity predicts viral rebound after travel to the tropics in HIV-infected travelers to the tropics in the Swiss HIV Cohort Study | HIV Medicine | 2017 | 388 | 0 | |||
| High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study | AIDS Care | 2017 | 412 | 632 | |||
| Human papillomavirus antibody response following HAART initiation among MSM | AIDS | 2017 | 429 | 0 | |||
| Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study | Clinical Infectious Diseases | 2017 | 396 | 0 | |||
| Virological Outcomes of Second-line Protease Inhibitor–Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis | Clinical Infectious Diseases | 2017 | 419 | 224 | |||
| Adverse events of raltegravir and dolutegravir | AIDS | 2017 | 427 | 182 | |||
| Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP) | The Lancet HIV | 2017 | 402 | 0 | |||
| Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study | BMC Infectious Diseases | 2017 | 423 | 182 | |||
| Blinded by Zika? A missed HIV diagnosis that resulted in optic neuropathy and blindness: a case report | BMC Research Notes | 2017 | 423 | 250 | |||
| Mining for pairs: shared clinic visit dates identify steady HIV-positive partnerships | HIV Medicine | 2017 | 449 | 0 | |||
| Associations Between Antiretroviral Treatment and Avascular Bone Necrosis: The Swiss HIV Cohort Study | Open Forum Infectious Diseases | 2017 | 397 | 176 | |||
| Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial | The Lancet HIV | 2017 | 417 | 0 | |||
| Impact of screening and antiretroviral therapy on anal cancer incidence in HIV-positive MSM | AIDS | 2017 | 591 | 401 | |||
| The J-Curve in HIV: Low and Moderate Alcohol Intake Predicts Mortality but Not the Occurrence of Major Cardiovascular Events | Journal of acquired immune deficiency syndromes | 2016 | 86 | 0 | |||
| Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy : The Swiss HIV Cohort Study | Open forum infectious diseases | 2016 | 86 | 73 | |||
| Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared | International journal of infectious diseases | 2016 | 513 | 187 | |||
| Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions | Hepatology | 2016 | 707 | 339 | |||
| Hepatitis C Virus Awareness Among Men Who Have Sex With Men in Southwest Switzerland | Sexually transmitted diseases | 2016 | 71 | 0 | |||
| Standard Genotyping Overestimates Transmission of Mycobacterium tuberculosis among Immigrants in a Low-Incidence Country | Journal of Clinical Microbiology | 2016 | 525 | 0 | |||
| HIV-Positive-to-HIV-Positive Liver Transplantation | American journal of transplantation | 2016 | 669 | 432 | |||
| Determinants of HIV-1 broadly neutralizing antibody induction | Nature Medicine | 2016 | 566 | 430 | |||
| Successful Prevention of Transmission of Integrase Resistance in the Swiss HIV Cohort Study | The Journal of Infectious Diseases | 2016 | 423 | 246 | |||
| Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection | The Journal of infectious diseases | 2016 | 60 | 0 | |||
| The 2014–2015 Ebola outbreak in West Africa: Hands On | Antimicrobial Resistance and Infection Control | 2016 | 542 | 237 | |||
| Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis | Clinical Infectious Diseases | 2016 | 681 | 1 | |||
| HIV-1 Transmission During Recent Infection and During Treatment Interruptions as Major Drivers of New Infections in the Swiss HIV Cohort Study | Clinical Infectious Diseases | 2016 | 519 | 214 | |||
| Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review | New microbes and new infections | 2015 | 612 | 1 | |||
| Increases in Condomless Sex in the Swiss HIV Cohort Study | Open forum infectious diseases | 2015 | 91 | 66 | |||
| Corrigendum to "Dolutegravir-based antiretroviral therapy in a severely overweight child with a multi-drug resistant human immunodeficiency virus infection. A case report and review" [New Microbes New Infect] 6 (2015) 1-4] | New microbes and new infections | 2015 | 505 | 0 | |||
| Transient detectable viremia and the risk of viral rebound in patients from the Swiss HIV Cohort Study | BMC infectious diseases | 2015 | 105 | 88 | |||
| Hit me with your best shot: dolutegravir - a space in the next WHO guidelines ? | AIDS | 2015 | 80 | 0 | |||
| Neighbourhood socio-economic position, late presentation and outcomes in people living with HIV in Switzerland | AIDS | 2015 | 95 | 0 | |||
| Choice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents : a systematic review | Clinical infectious diseases | 2015 | 79 | 0 | |||
| Is monotherapy maintenance the way forward ? | The lancet. HIV | 2015 | 68 | 77 | |||
| Reasons for late presentation to HIV care in Switzerland | Journal of the International AIDS Society | 2015 | 74 | 46 | |||
| Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | 2015 | 103 | 35 | |||
| Addressing social issues in a universal HIV test and treat intervention trial (ANRS 12249 TasP) in South Africa: methods for appraisal | BMC public health | 2015 | 90 | 66 | |||
| Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study | European journal of clinical investigation | 2015 | 609 | 0 | |||
| The future role of CD4 cell count for monitoring antiretroviral therapy | Lancet. Infectious diseases | 2015 | 508 | 0 | |||
| Prise en charge du VIH/sida en 2015 | Revue médicale suisse | 2015 | 78 | 56 | |||
| HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons | BMC gastroenterology | 2015 | 79 | 34 | |||
| Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa | AIDS | 2015 | 109 | 107 | |||
| Evidence on the protective role of high-density lipoprotein (HDL) in HIV-infected individuals | Current vascular pharmacology | 2015 | 688 | 0 | |||
| Syphilis: Diagnostik und Behandlung | Swiss Medical Forum | 2015 | 385 | 1,013 | |||
| Generating Evidence to Improve the Response to Neglected Diseases : How Operational Research in a Médecins Sans Frontières Buruli Ulcer Treatment Programme Informed International Management Guidance | PLoS neglected tropical diseases | 2015 | 70 | 19 | |||
| World Health Organization Guidelines on Postexposure Prophylaxis for HIV : Recommendations for a Public Health Approach | Clinical infectious diseases | 2015 | 65 | 0 | |||
| Self-reported nonadherence to antiretroviral therapy as a predictor of viral failure and mortality | AIDS | 2015 | 76 | 0 | |||
| Hyaluronic Acid Filler in HIV-Associated Facial Lipoatrophy: Evaluation of Tissue Distribution and Morphology with MRI | Dermatology | 2015 | 769 | 1 | |||
| Strong Impact of Smoking on Multimorbidity and Cardiovascular Risk Among Human Immunodeficiency Virus-Infected Individuals in Comparison With the General Population | Open forum infectious diseases | 2015 | 606 | 266 | |||
| Lipodystrophy among HIV-infected patients: a cross-sectional study on impact on quality of life and mental health disorders | AIDS research and therapy | 2015 | 626 | 333 | |||
| Clustering of HCV coinfections on HIV phylogeny indicates domestic and sexual transmission of HCV | International journal of epidemiology | 2014 | 774 | 456 | |||
| Disentangling human tolerance and resistance against HIV | PLoS biology | 2014 | 667 | 350 | |||
| Clinical significance of the CCR5delta32 allele in hepatitis C | PloS one | 2014 | 586 | 255 | |||
| The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients | AIDS | 2014 | 570 | 0 | |||
| Haemophagocytic syndrome and elevated EBV load as initial manifestation of Hodgkin lymphoma in a HIV patient: case report and review of the literature | Journal of the International AIDS Society | 2014 | 586 | 456 | |||
| AIDS defining opportunistic infections in patients with high CD4 counts in the combination antiretroviral therapy (cART) era: things ain't what they used to be | Journal of the International AIDS Society | 2014 | 638 | 294 | |||
| Limited clinical benefit of minority K103N and Y181C-variant detection in addition to routine genotypic resistance testing in antiretroviral therapy-naive patients | AIDS | 2014 | 572 | 0 | |||
| Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapy | TM & IH. Tropical medicine and international health | 2014 | 615 | 544 | |||
| Treatment-Naive Individuals Are the Major Source of Transmitted HIV-1 Drug Resistance in Men Who Have Sex With Men in the Swiss HIV Cohort Study | Clinical infectious diseases | 2014 | 718 | 0 | |||
| Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity | AIDS research and therapy | 2014 | 738 | 966 | |||
| Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis | AIDS | 2014 | 492 | 0 | |||
| Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia | Clinical infectious diseases | 2014 | 730 | 308 | |||
| Social Meets Molecular: Combining Phylogenetic and Latent Class Analyses to Understand HIV-1 Transmission in Switzerland | American journal of epidemiology | 2014 | 874 | 81 | |||
| Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide | The Journal of infectious diseases | 2014 | 605 | 0 | |||
| Lipohypertrophy and metabolic disorders in HIV patients on antiretroviral therapy: a systematic multidisciplinary clinical approach | Journal of the International AIDS Society | 2014 | 622 | 1,386 | |||
| Virologic and immunologic responses in treatment-naive patients to ritonavir-boosted atazanavir or efavirenz with a common backbone | HIV clinical trials | 2014 | 83 | 0 | |||
| Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study | Antimicrobial agents and chemotherapy | 2014 | 911 | 613 | |||
| Impact of human immunodeficiency virus on the severity of buruli ulcer disease: results of a retrospective study in cameroon | Open forum infectious diseases | 2014 | 529 | 360 | |||
| Microstructural alterations of trabecular and cortical bone in long-term HIV-infected elderly men on successful antiretroviral therapy | AIDS | 2014 | 813 | 673 | |||
| Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment | Antimicrobial agents and chemotherapy | 2014 | 149 | 0 | |||
| Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis | AIDS | 2014 | 557 | 2 | |||
| Obesity Trends and Body Mass Index Changes After Starting Antiretroviral Treatment: The Swiss HIV Cohort Study | Open forum infectious diseases | 2014 | 986 | 358 | |||
| Réplication cérébrale du VIH malgré une thérapie antirétrovirale efficace: impact clinique et prise en charge | Revue médicale suisse | 2014 | 810 | 464 | |||
| Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection | The American journal of cardiology | 2013 | 632 | 0 | |||
| Evaluation of the impact of immediate versus WHO recommendations-guided antiretroviral therapy initiation on HIV incidence : the ANRS 12249 TasP (Treatment as Prevention) trial in Hlabisa sub-district, KwaZulu-Natal, South Africa : study protocol for a cluster randomised controlled trial | Trials | 2013 | 108 | 22 | |||
| Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection | The Journal of infectious diseases | 2013 | 657 | 0 | |||
| Adverse events associated with nevirapine use in pregnancy: a systematic review and meta-analysis | AIDS | 2013 | 598 | 0 | |||
| HIV-infected women in Europe: gender-specific needs and challenges | Antiviral therapy | 2013 | 626 | 0 | |||
| Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study | American journal of epidemiology | 2013 | 676 | 0 | |||
| Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapy: a systematic review and meta-analysis | AIDS | 2013 | 635 | 0 | |||
| Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study | HIV medicine | 2013 | 644 | 0 | |||
| Clinical Course and Management of Iatrogenic Cushing's Syndrome after Co-Administration of Injected-Triamcinolone and Ritonavir: a Systematic Review | Journal of Antivirals and Antiretrovirals | 2013 | 1,231 | 404 | |||
| Les os des personnes infectées par le VIH sont-ils si fragiles? | Revue médicale suisse | 2013 | 634 | 0 | |||
| The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients | PLoS computational biology | 2013 | 708 | 290 | |||
| HIV infection disrupts the sympatric host-pathogen relationship in human tuberculosis | PLOS genetics | 2013 | 930 | 652 | |||
| Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals | Pharmacogenetics and genomics | 2013 | 664 | 0 | |||
| Intracranial hypertension following highly active antiretroviral therapy interruption in an HIV-infected woman: case report and review of the literature | AIDS | 2013 | 635 | 0 | |||
| La prophylaxie postexposition dans tous ses états | Revue médicale suisse | 2013 | 611 | 0 | |||
| VIH/sida : une sélection des nouveautés les plus prometteuses en 2012 | Revue médicale suisse | 2013 | 572 | 2 | |||
| Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal women | Osteoporosis international | 2013 | 832 | 312 | |||
| Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study | Neurology | 2013 | 824 | 1 | |||
| Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study | PloS one | 2013 | 624 | 602 | |||
| Risk of cardiovascular events and blood pressure control in hypertensive HIV-infected patients: Swiss HIV Cohort Study (SHCS) | Journal of acquired immune deficiency syndromes | 2013 | 610 | 0 | |||
| Pulmonary embolism and iatrogenic Cushing's syndrome after co-administration of injected-triamcinolone and ritonavir | AIDS | 2013 | 580 | 401 | |||
| Association of Alcohol Consumption and HIV Surrogate Markers in Participants of the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | 2013 | 578 | 0 | |||
| Bénéfices d'un accompagnement psychologique des patients vivant avec le VIH | Revue médicale suisse | 2013 | 736 | 0 | |||
| Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial | Lancet. Infectious diseases | 2013 | 957 | 0 | |||
| Micro-Structural Brain Alterations in Aviremic HIV+ Patients with Minor Neurocognitive Disorders: A Multi-Contrast Study at High Field | PloS one | 2013 | 812 | 1,185 | |||
| Hepatitis B virus infection is associated with impaired immunological recovery during antiretroviral therapy in the Swiss HIV cohort study | The Journal of infectious diseases | 2013 | 653 | 0 | |||
| Produits de comblement du visage : dispositifs médicaux ou médicaments ? Implication pour les patients VIH+ atteints de lipoatrophie | Revue médicale suisse | 2012 | 596 | 0 | |||
| Efavirenz is not a known teratogen | The Pediatric infectious disease journal | 2012 | 560 | 0 | |||
| Expert reviews: who are they for? | Expert opinion on pharmacotherapy | 2012 | 570 | 0 | |||
| Preferred antiretroviral drugs for the next decade of scale up | Journal of the International AIDS Society | 2012 | 551 | 462 | |||
| Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection | British journal of cancer | 2012 | 585 | 1,091 | |||
| Serotonin syndrome following drug-drug interactions and CYP2D6 and CYP2C19 genetic polymorphisms in an HIV-infected patient | AIDS | 2012 | 636 | 635 | |||
| Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings | HIV/AIDS[1179-1373] | 2012 | 757 | 910 | |||
| Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir | AIDS | 2012 | 616 | 0 | |||
| Drug interactions between voriconazole, darunavir/ritonavir and etravirine in an HIV-infected patient with Aspergillus pneumonia | AIDS | 2012 | 671 | 0 | |||
| Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis | Antimicrobial agents and chemotherapy | 2012 | 884 | 1,251 | |||
| Buruli et VIH: une interaction complexe et peu étudiée | Revue médicale suisse | 2012 | 524 | 0 | |||
| Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection | Journal of clinical microbiology | 2012 | 982 | 1,683 | |||
| Higher memory responses in HIV-infected and kidney transplanted patients than in healthy subjects following priming with the pandemic vaccine | PloS one | 2012 | 773 | 353 | |||
| Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens | PloS one | 2012 | 642 | 280 | |||
| VIH/SIDA | Revue médicale suisse | 2012 | 533 | 1 | |||
| Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians | HIV medicine | 2012 | 599 | 0 | |||
| Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic | Clinical infectious diseases | 2012 | 564 | 0 | |||
| All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration | International journal of epidemiology | 2012 | 681 | 0 | |||
| Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients | HIV medicine | 2012 | 724 | 0 | |||
| Longer term clinical and virological outcome of sub-Saharan African participants on antiretroviral treatment in the Swiss HIV Cohort Study | Journal of acquired immune deficiency syndromes | 2012 | 637 | 0 | |||
| Mean CD4 cell count changes in patients failing a first-line antiretroviral therapy in resource-limited settings | BMC infectious diseases | 2012 | 627 | 447 | |||
| Défis de la co-infection par le virus de l'hépatite C et le VIH | Revue médicale suisse | 2012 | 622 | 0 | |||
| Participation, characteristics and retention rates of HIV-positive immigrants in the Swiss HIV Cohort Study | HIV medicine | 2012 | 637 | 1 | |||
| Viral load monitoring in resource-limited settings: a medical and public health priority | AIDS | 2012 | 536 | 1 | |||
| Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients | PloS one | 2012 | 637 | 250 | |||
| Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011 | Clinical infectious diseases | 2012 | 637 | 575 | |||
| Impact of highly active antiretroviral therapy on the molecular epidemiology of newly diagnosed HIV infections | AIDS | 2012 | 743 | 448 | |||
| Impact of a nurse vaccination program on hepatitis B immunity in a Swiss HIV clinic | Journal of acquired immune deficiency syndromes | 2011 | 76 | 0 | |||
| Graft-versus-host disease is the major determinant of humoral responses to the AS03-adjuvanted influenza A/09/H1N1 vaccine in allogeneic hematopoietic stem cell transplant recipients | Haematologica | 2011 | 1,053 | 635 | |||
| Ageing with HIV : medication use and risk for potential drug-drug interactions | The journal of antimicrobial chemotherapy | 2011 | 60 | 0 | |||
| Squamous cell carcinoma of the anus-an opportunistic cancer in HIV-positive male homosexuals | World journal of gastroenterology | 2011 | 949 | 670 | |||
| Successful efavirenz dose reduction guided by therapeutic drug monitoring | Antiviral therapy | 2011 | 60 | 0 | |||
| Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis | AIDS | 2011 | 68 | 0 | |||
| Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: a prospective, open-label, parallel-cohort, single-center study | Arthritis and rheumatism | 2011 | 879 | 8 | |||
| Estimating loss to follow-up in HIV-infected patients on antiretroviral therapy: the effect of the competing risk of death in Zambia and Switzerland | PloS one | 2011 | 1,280 | 373 | |||
| Co-infection tuberculose et VIH: enjeux thérapeutiques | Revue médicale suisse | 2011 | 670 | 0 | |||
| Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients : The ACHIEV2E Collaboration Study Group | Clinical infectious diseases | 2011 | 104 | 0 | |||
| VIH/SIDA : nombreuses nouveautés | Revue médicale suisse | 2011 | 75 | 140 | |||
| A randomized crossover study to compare efavirenz and etravirine treatment | AIDS | 2011 | 105 | 0 | |||
| Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings | HIV/AIDS | 2011 | 752 | 577 | |||
| The first decade of antiretroviral therapy in Africa | Globalization and health | 2011 | 80 | 30 | |||
| HIV treatment for prevention | Journal of the International AIDS Society | 2011 | 69 | 42 | |||
| Clinical relevance of cytomegalovirus viraemia | HIV medicine | 2011 | 659 | 0 | |||
| Pharmacokinetics and pharmacogenomics of once-daily raltegravir and atazanavir in healthy volunteers | Antimicrobial agents and chemotherapy | 2010 | 640 | 0 | |||
| Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study | Antiviral therapy | 2010 | 574 | 0 | |||
| ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir | Pharmacogenetics and genomics | 2010 | 706 | 0 | |||
| Improving first-line antiretroviral therapy in resource-limited settings | Current opinion in HIV and AIDS | 2010 | 560 | 0 | |||
| Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts | AIDS | 2010 | 548 | 0 | |||
| Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection | The Journal of infectious diseases | 2010 | 630 | 359 | |||
| Reduction of missed appointments at an urban primary care clinic: a randomised controlled study | BMC family practice | 2010 | 691 | 474 | |||
| Treatment of HIV infection with drugs for HSV-2 infection | Lancet | 2010 | 531 | 0 | |||
| Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study | British journal of cancer | 2010 | 798 | 1 | |||
| Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries | JAMA | 2010 | 588 | 0 | |||
| Optimizing HIV drug therapy | 2010 | 664 | 1,865 | ||||
| High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy | HIV medicine | 2010 | 628 | 0 | |||
| Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon | BMC public health | 2010 | 652 | 263 | |||
| High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients | AIDS | 2010 | 601 | 0 | |||
| Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia | Clinical infectious diseases | 2010 | 617 | 0 | |||
| Hyaluronic acid injections to fill facial lipoatrophy in the context of a lipodystrophy syndrome associated with HIV | Dermatologica Helvetica | 2010 | 257 | 86 | |||
| No significant effect of uridine or pravastatin treatment for HIV lipoatrophy in men who have ceased thymidine analogue nucleoside reverse transcriptase inhibitor therapy: a randomized trial | HIV medicine | 2010 | 587 | 0 | |||
| Patient needs and point-of-care requirements for HIV load testing in resource-limited settings | The Journal of infectious diseases | 2010 | 588 | 0 | |||
| Cognitive dysfunction in HIV patients despite long-standing suppression of viremia | AIDS | 2010 | 919 | 1 | |||
| When to start antiretroviral therapy in resource-limited settings: a human rights analysis | BMC international health and human rights | 2010 | 632 | 377 | |||
| Health perceptions of African HIV-infected patients and their physicians | Patient education and counseling | 2010 | 654 | 0 | |||
| A new era of antiretroviral drug toxicity | Antiviral therapy | 2009 | 598 | 0 | |||
| Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring | AIDS | 2009 | 93 | 0 | |||
| Education thérapeutique en maladie infectieuse : l'exemple de l'infection à VIH | Revue médicale suisse | 2009 | 653 | 0 | |||
| HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial | AIDS | 2009 | 662 | 0 | |||
| Safety and efficacy of once-daily nevirapine dosing: a multicohort study | Antiviral therapy | 2009 | 660 | 0 | |||
| Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine : a nested case-control study | Clinical infectious diseases | 2009 | 79 | 0 | |||
| Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study | The Journal of infectious diseases | 2009 | 601 | 0 | |||
| Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients | Antiviral therapy | 2009 | 60 | 0 | |||
| How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals | Drug discovery today | 2008 | 90 | 0 | |||
| Dix ans de lipodystrophie (1998-2008) : un syndrome encore méconnu | Revue médicale suisse | 2008 | 591 | 212 | |||
| Adherence to antiretroviral therapy assessed by drug level monitoring and self-report in Cameroon | Journal of acquired immune deficiency syndromes | 2008 | 77 | 0 | |||
| The marriage of science and optimized HIV care in resource-limited settings | AIDS | 2008 | 73 | 0 | |||
| Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching | AIDS | 2008 | 82 | 0 | |||
| Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy | HIV medicine | 2008 | 81 | 0 | |||
| Initial treatment for HIV infection--an embarrassment of riches | The New England journal of medicine | 2008 | 606 | 0 | |||
| Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006 | HIV medicine | 2008 | 610 | 0 | |||
| 10 Jahren Lipodystrophie (1998-2008): Die "Groupe Lipo" der Hôpitaux universitaires de Genève: Ein Beratungsangebot für VIH-Positive mit dem Lipodystrophie-Syndrome | Dermatologica Helvetica | 2008 | 235 | 44 | |||
| Clinical update: adverse effects of antiretroviral therapy | Lancet | 2007 | 627 | 0 | |||
| HIV viral load monitoring in resource-limited regions: optional or necessary? | Clinical infectious diseases | 2007 | 626 | 1 | |||
| Treating HIV in the developing world: getting ahead of the drug development curve | Drug discovery today | 2007 | 64 | 0 | |||
| Generic fixed-dose combination antiretroviral treatment in resource-poor settings : multicentric observational cohort | AIDS | 2006 | 80 | 0 | |||
| Field assessment of generic antiretroviral drugs : a prospective cohort study in Cameroon | Antiviral therapy | 2005 | 91 | 0 | |||
| Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine | AIDS | 2004 | 73 | 0 | |||
| Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy | Clinical infectious diseases | 2004 | 68 | 0 | |||
| First-line and second-line antiretroviral therapy | Lancet | 2004 | 71 | 0 | |||
| Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial | Lancet | 2004 | 86 | 0 | |||
| HIV drug resistance | The New England journal of medicine | 2004 | 55 | 65 | |||
| Glitazones in lipodystrophy syndrome induced by highly active antiretroviral therapy | AIDS | 2003 | 545 | 0 | |||
| Highly active antiretroviral therapy in resource-poor settings: the experience of Médecins Sans Frontières | AIDS | 2003 | 56 | 0 |
